SchiffmanIScheiderbauerJRiemann-LorenzKet al. Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?Mult Scler2018; 24: 1387–1388.
2.
De StefanoNGiorgioABattagliniMet al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018; 24: 222–226.
3.
De StefanoNAirasLGrigoriadisNet al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs2014; 28(2): 147–156.
4.
WattjesMPRoviraAMillerDet al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11: 597–606.
5.
BarkhofFSimonJHFazekasFet al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol2011; 8(1): 13–21.
6.
ArnoldDLGoldRKapposLet al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014; 261(9): 1794–1802.
7.
HauserSLBar-OrAComiGet al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
8.
MontalbanXHauserSLKapposLet al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376(3): 209–220.
9.
De StefanoNSilvaDGBarnettMH. Effect of fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs2017; 31(4): 289–305.
10.
MillerDHSoonDFernandoKTet al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology2007; 68(17): 1390–1401.
11.
Sastre-GarrigaJParetoDRoviraA.Brain atrophy in multiple sclerosis: Clinical relevance and technical aspects. Neuroimaging Clin N Am2017; 27(2): 289–300.
12.
De StefanoNArnoldDL. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult Scler2015; 21(6): 675–676.
